GlobeNewswire Inc | Jan 5, 2021 07:00AM EST

January 05, 2021

Silence Therapeutics to Participate in January Virtual U.S. Investor Conferences

5 January 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will participate in a fireside chat at two upcoming investor conferences, details of which can be found below:

H.C. Wainwright BioConnect 2021 Conference

Date: January 11, 2021Time: 6:00 a.m. EST (13:00 GMT)

ICR Conference 2021

Date: Thursday, January 14, 2021Time: 8:30- 9:10 a.m. EST (13:30 - 14:10 GMT)

Live webcasts of the Company's presentations can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcasts will be available for 60 days on the Company's website following the conference.

Enquiries:

Silence Therapeutics plcGem Hopkins, Head of IR and CorporateCommunications Tel: +1 (646) 637-3208ir@silence-therapeutics.com

Investec Bank plc (Nominated Adviser andBroker) Tel: +44 (0) 20 7597Daniel Adams/Gary Clarence 5970

European IRConsilium Strategic CommunicationsMary-Jane Elliott/ Angela Gray / Chris Welsh Tel: +44 (0) 20 3709 5700silencetherapeutics@consilium-comms.com

U.S. IRWestwickePeter Vozzo Tel: +1 (443) 213-0505peter.vozzo@westwicke.com

About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the bodys natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silences proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silences wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/